Haemonetics Corporation (HAE) to Post FY2019 Earnings of $2.00 Per Share, Jefferies Group Forecasts

Haemonetics Corporation (NYSE:HAE) – Equities research analysts at Jefferies Group increased their FY2019 EPS estimates for shares of Haemonetics in a report issued on Monday. Jefferies Group analyst A. Petrone now forecasts that the medical instruments supplier will post earnings of $2.00 per share for the year, up from their prior forecast of $1.95. Jefferies Group has a “Buy” rating and a $75.00 price objective on the stock.

Haemonetics (NYSE:HAE) last issued its earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.07. The firm had revenue of $225.40 million for the quarter, compared to analyst estimates of $219.12 million. Haemonetics had a net margin of 0.50% and a return on equity of 11.16%. The company’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter last year, the business posted $0.38 earnings per share.

Several other research firms also recently issued reports on HAE. Zacks Investment Research raised shares of Haemonetics from a “hold” rating to a “buy” rating and set a $70.00 price target for the company in a research note on Tuesday. Raymond James Financial raised shares of Haemonetics from an “underperform” rating to a “market perform” rating in a research note on Tuesday, January 2nd. Morgan Stanley raised shares of Haemonetics from an “equal weight” rating to an “overweight” rating and set a $51.00 price target for the company in a research note on Tuesday, January 2nd. Craig Hallum reaffirmed a “hold” rating and set a $50.00 price target (up previously from $40.00) on shares of Haemonetics in a research note on Wednesday, November 8th. Finally, Barrington Research raised their price target on shares of Haemonetics from $48.00 to $57.00 and gave the company an “outperform” rating in a research note on Wednesday, November 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. Haemonetics has an average rating of “Buy” and a consensus price target of $58.83.

Haemonetics (NYSE:HAE) traded up $0.76 during mid-day trading on Tuesday, hitting $63.39. 426,840 shares of the stock traded hands, compared to its average volume of 577,950. The company has a market capitalization of $3,320.00, a P/E ratio of 905.57, a P/E/G ratio of 4.71 and a beta of 0.99. Haemonetics has a 12-month low of $36.44 and a 12-month high of $63.90. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.17 and a quick ratio of 1.51.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Riverhead Capital Management LLC raised its stake in Haemonetics by 79.3% during the second quarter. Riverhead Capital Management LLC now owns 3,407 shares of the medical instruments supplier’s stock worth $135,000 after buying an additional 1,507 shares during the last quarter. Pacad Investment Ltd. bought a new position in Haemonetics during the second quarter worth $174,000. Shelton Capital Management bought a new position in Haemonetics during the second quarter worth $204,000. Cubist Systematic Strategies LLC bought a new position in Haemonetics during the second quarter worth $260,000. Finally, SG Americas Securities LLC bought a new position in Haemonetics during the third quarter worth $316,000.

In related news, Director Mark W. Kroll sold 7,118 shares of Haemonetics stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $63.00, for a total transaction of $448,434.00. Following the completion of the transaction, the director now owns 33,881 shares of the company’s stock, valued at $2,134,503. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CAO Dan Goldstein sold 4,691 shares of Haemonetics stock in a transaction on Monday, November 13th. The stock was sold at an average price of $54.93, for a total transaction of $257,676.63. Following the transaction, the chief accounting officer now directly owns 3,747 shares of the company’s stock, valued at approximately $205,822.71. The disclosure for this sale can be found here. Insiders have sold 54,486 shares of company stock valued at $3,050,827 in the last ninety days. Insiders own 1.20% of the company’s stock.

WARNING: “Haemonetics Corporation (HAE) to Post FY2019 Earnings of $2.00 Per Share, Jefferies Group Forecasts” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.com-unik.info/2018/01/09/haemonetics-corporation-hae-to-post-fy2019-earnings-of-2-00-per-share-jefferies-group-forecasts.html.

About Haemonetics

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Earnings History and Estimates for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit